Meeting
2018 ASCO Annual Meeting
CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).
Authors
Harry H. Yoon
Mayo Clinic, Rochester, MN
Harry H. Yoon , Qian Shi , Erica N Heying , Andrea Muranyi , Faith Ough , Azita Djalilvand , June Clements , Rebecca Bowermaster , Wen-Wei Liu , Michael Barnes , Steven R. Alberts , Kandavel Shanmugam , Frank A. Sinicrope
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3598)
DOI
10.1200/JCO.2018.36.15_suppl.3598
Abstract #
3598
Poster Bd #
91
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2022 ASCO Annual Meeting
Effect of more versus less frequent abdominopelvic computed tomography follow-up testing on overall survival in patients with stage II or III colon cancer.
First Author: Jeon Jeongseok
Poster
2018 ASCO Annual Meeting
Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).
First Author: Frank A. Sinicrope
Poster
2018 ASCO Annual Meeting
Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).
First Author: Jeanne Tie